PRTK
Closed
Paratek Pharmaceuticals Inc
2.23
0.00 (0.00%)
Last Update: 29 Sep 2023 16:30:00
Yesterday: 2.23
Day's Range: 2.23 - 2.23
Send
sign up or login to leave a comment!
When Written:
2.65
Paratek Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies based on its proprietary tetracycline chemistry. The company's lead product is NUZYRA, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Paratek Pharmaceuticals was founded in 1996 and is headquartered in Boston, Massachusetts. The company has a global presence, with offices in the United States, Europe, and Asia. Its research and development efforts are focused on the discovery and development of novel antibiotics to address the growing problem of antibiotic resistance.
In addition to NUZYRA, Paratek Pharmaceuticals has a pipeline of other product candidates in various stages of development, including a novel antibiotic for the treatment of urinary tract infections (UTIs) and a topical antibiotic for the treatment of acne. The company has partnerships with leading pharmaceutical companies, including Allergan and Zai Lab, to help bring its products to market.
Paratek Pharmaceuticals is committed to improving the lives of patients by developing innovative therapies to address unmet medical needs. The company is dedicated to advancing the science of antibiotic development and is actively working to combat the global threat of antibiotic resistance.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Paratek Pharmaceuticals was founded in 1996 and is headquartered in Boston, Massachusetts. The company has a global presence, with offices in the United States, Europe, and Asia. Its research and development efforts are focused on the discovery and development of novel antibiotics to address the growing problem of antibiotic resistance.
In addition to NUZYRA, Paratek Pharmaceuticals has a pipeline of other product candidates in various stages of development, including a novel antibiotic for the treatment of urinary tract infections (UTIs) and a topical antibiotic for the treatment of acne. The company has partnerships with leading pharmaceutical companies, including Allergan and Zai Lab, to help bring its products to market.
Paratek Pharmaceuticals is committed to improving the lives of patients by developing innovative therapies to address unmet medical needs. The company is dedicated to advancing the science of antibiotic development and is actively working to combat the global threat of antibiotic resistance.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!